Objective and subjective cognitive outcomes one year after COVID-19.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
19 Jul 2024
Historique:
revised: 17 06 2024
received: 17 04 2024
accepted: 07 07 2024
medline: 20 7 2024
pubmed: 20 7 2024
entrez: 20 7 2024
Statut: aheadofprint

Résumé

This study aimed to evaluate subjective cognitive, physical, and mental health symptoms as well as objective cognitive deficits in COVID-19 patients 1 year after infection. This was a cross-sectional study. Seventy-four patients, who contracted a SARS-CoV-2 infection in 2020, underwent an in-person neuropsychological assessment in 2021. This included standardized tests of memory, attention, and executive functions. In addition, participants also responded to scales on subjective attention deficits, mental health symptoms, and fatigue. Patients' scores were compared to published norms. Patients (N = 74) had a median age of 56 years (42% female). According to the initial disease severity, they were classified as mild (outpatients, 32%), moderate (hospitalized, non-ICU-admitted, 45%), or severe (ICU-admitted, 23%). Hospitalized patients were more often affected than outpatients. In general, deficits were most common in attention (23%), followed by memory (15%) and executive functions (3%). Patients reported increased levels of fatigue (51%), anxiety (30%), distractibility in everyday situations (20%), and depression (15%). An additional analysis suggested an association between lower scores in an attention task and hyperferritinemia. As indicated by a hierarchical regression analysis, subjective distractibility was significantly predicted by current anxiety and fatigue symptoms but not by objective attention performance (final model, adj-R One year after infection, COVID-19 patients can have frequent attention deficits and can complain about symptoms such as fatigue, anxiety, and distractibility. Anxiety and fatigue, more than objective cognitive deficits, have an impact on the patients' experienced impairments in everyday life.

Identifiants

pubmed: 39031013
doi: 10.1002/acn3.52149
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Austrian Science Fund
ID : KLI 986

Informations de copyright

© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid‐19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136.
Lopez‐Leon S, Wegman‐Ostrosky T, Perelman C, et al. More than 50 long‐term effects of COVID‐19: a systematic review and meta‐analysis. Sci Rep. 2021;11(1):16144.
Crispo A, Bimonte S, Porciello G, et al. Strategies to evaluate outcomes in long‐COVID‐19 and post‐COVID survivors. Infect Agent Cancer. 2021;16(1):62.
Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS‐CoV‐2 infection. N Engl J Med. 2020;382(23):2268‐2270.
Crivelli L, Palmer K, Calandri I, et al. Changes in cognitive functioning after COVID‐19: a systematic review and meta‐analysis. Alzheimers Dement. 2022;18(5):1047‐1066.
Bertuccelli M, Ciringione L, Rubega M, Bisiacchi P, Masiero S, del Felice A. Cognitive impairment in people with previous COVID‐19 infection: a scoping review. Cortex. 2022;154:212‐230.
Tavares‐Júnior JWL, de Souza ACC, Borges JWP, et al. COVID‐19 associated cognitive impairment: a systematic review. Cortex. 2022;152:77‐97.
Cosentino G, Todisco M, Hota N, et al. Neuropathological findings from COVID‐19 patients with neurological symptoms argue against a direct brain invasion of SARS‐CoV‐2: a critical systematic review. Eur J Neurol. 2021;28(11):3856‐3865.
Azcue N, Gómez‐Esteban JC, Acera M, et al. Brain fog of post‐COVID‐19 condition and chronic fatigue syndrome, same medical disorder? J Transl Med. 2022;20(1):569.
Carbone F, Zamarian L, Rass V, et al. Cognitive dysfunction 1 year after COVID‐19: evidence from eye tracking. Ann Clin Transl Neurol. 2022;9(11):1826‐1831.
Larsson I‐M, Hultström M, Lipcsey M, Frithiof R, Rubertsson S, Wallin E. Poor long‐term recovery after critical COVID‐19 during 12 months longitudinal follow‐up. Intensive Crit Care Nurs. 2022;74:103311.
Rass V, Ianosi B‐A, Zamarian L, et al. Factors associated with impaired quality of life three months after being diagnosed with COVID‐19. Qual Life Res. 2022;31(5):1401‐1414.
Rass V, Beer R, Schiefecker AJ, et al. Neurological outcomes 1 year after COVID‐19 diagnosis: a prospective longitudinal cohort study. Eur J Neurol. 2022;29(6):1685‐1696.
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695‐699.
Härting C, Markowitsch HJ, Neufeld H, et al. WMS‐R Wechsler Gedächtnistest—Revidierte Fassung. Hans Huber; 2000.
Rodewald K, Bartolovic M, Debelak R, Aschenbrenner S, Weisbrod M, Roesch‐Ely D. Eine Normierungsstudie eines modifizierten Trail Making Tests im deutschsprachigen Raum. Z Für Neuropsychol. 2012;23(1):37‐48.
Aschenbrennen S, Tucha O, Lange KW. Regensburger Wortflüssigkeits‐Test. Hogrefe; 2001.
Petermann F, Jäncke L, Waldmann H‐C. Neuropsychological Assessment Battery – Deutschsprachige Adaptation der Neuropsychological Assessment Battery (NAB) von Robert A. Stern und Travis White. 1. Hogrefe; 2016.
Lezak MD. Neuropsychological Assessment. Oxford University Press; 1985.
Hermann C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale—German (HADS‐D). Hans Huber; 1995.
De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004;9(Pt 3):279‐291.
Sturm W. Aufmerksamkeitsstörungen. Hogrefe; 2005.
Hoffman LA, Vilensky JA. Encephalitis lethargica: 100 years after the epidemic. Brain J Neurol. 2017;140(8):2246‐2251.
Verstrepen K, Baisier L, De Cauwer H. Neurological manifestations of COVID‐19, SARS and MERS. Acta Neurol Belg. 2020;120(5):1051‐1060.
Mayerhöfer T, Perschinka F, Klein SJ, et al. Incidence, risk factors and outcome of acute kidney injury in critically ill COVID‐19 patients in Tyrol, Austria: a prospective multicenter registry study. J Nephrol. 2023;36(9):2531‐2540.
Rengel KF, Hayhurst CJ, Pandharipande PP, Hughes CG. Long‐term cognitive and functional impairments after critical illness. Anesth Analg. 2019;128(4):772‐780.
Latronico N, Eikermann M, Ely EW, Needham DM. Improving management of ARDS: uniting acute management and long‐term recovery. Crit Care. 2024;28(1):58.
Lorent N, Vande Weygaerde Y, Claeys E, et al. Prospective longitudinal evaluation of hospitalised COVID‐19 survivors 3 and 12 months after discharge. ERJ Open Res. 2022;8(2):00004‐02022.
Huang L, Yao Q, Gu X, et al. 1‐year outcomes in hospital survivors with COVID‐19: a longitudinal cohort study. Lancet. 2021;398(10302):747‐758.
Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1‐year survival following intensive care unit treatment for COVID‐19. JAMA. 2022;327(6):559‐565.
Rass V, Beer R, Schiefecker AJ, et al. Neurological outcome and quality of life 3 months after COVID‐19: a prospective observational cohort study. Eur J Neurol. 2021;28(10):3348‐3359.
Liu Y‐H, Chen Y, Wang Q‐H, et al. One‐year trajectory of cognitive changes in older survivors of COVID‐19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol. 2022;79(5):509‐517.
Iadecola C, Anrather J, Kamel H. Effects of COVID‐19 on the nervous system. Cell. 2020;183(1):16‐27.e1.
Zhou M, Yin Z, Xu J, et al. Inflammatory profiles and clinical features of coronavirus 2019 survivors 3 months after discharge in Wuhan, China. J Infect Dis. 2021;224(9):1473‐1488.
Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long‐term consequences of COVID‐19 infections for the development of neurological disease. Alzheimers Res Ther. 2020;12(1):69.
Sandnes M, Ulvik RJ, Vorland M, Reikvam H. Hyperferritinemia‐a clinical overview. J Clin Med. 2021;10(9):2008.
Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID‐19 are associated with non‐resolving lung pathologies and poor patients' performance: a prospective observational cohort study. Respir Res. 2020;21(1):276.

Auteurs

Laura Zamarian (L)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Verena Rass (V)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Elisabeth Goettfried (E)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Valentina Mayr (V)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Federico Carbone (F)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Philipp Kindl (P)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Margarete Delazer (M)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Atbin Djamshidian (A)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Alessandra Fanciulli (A)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Philipp Mahlknecht (P)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Beatrice Heim (B)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Marina Peball (M)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Alois Josef Schiefecker (AJ)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Klaus Seppi (K)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Department of Neurology, Provincial Hospital of Kufstein, Kufstein, Austria.

Judith Löffler-Ragg (J)

Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Department of Pneumology, State Hospital of Hochzirl-Natters, Natters, Austria.

Ronny Beer (R)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Bettina Pfausler (B)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Stefan Kiechl (S)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Raimund Helbok (R)

Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Department of Neurology, Johannes Kepler University Linz, Linz, Austria.

Classifications MeSH